NET RETREAT the CCTG NE1 trial has recently opened in North America looking to compare retreatment of Peptide Receptor Radionuclide Therapy versus standard treatment in patients with metastatic midgut neuroendocrine tumours.
Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Positive Advanced Gastroesophageal Adenocarcinoma
Ibrutinib Combination Therapy in Transplant Ineligible Individuals with Newly Diagnosed Primary CNS Lymphoma
A Biomarker Sub-study of the CCTG ME.13 Duration of Anti PD-1 Therapy in Metastatic Melanoma STOP-GAP Trial
Fixed Duration vs Continuous Daratumumab in Transplant Ineligible Older Adults with Newly Diagnosed Multiple Myeloma
A Phase III Randomized Study of Nivolumab (Opdivo) or Brentuximab Vedotin (Adcetris) plus AVD in Patients (age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
MRD Driven Study of Venetoclax + Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk AML
Master Screening and Reassessment Protocol (MYELOMATCH) for the NCI myeloMATCH clinical trials
Novel Therapeutics in Younger Patients with High-Risk AML (MM1YA-S01)
Eradicating MRD in patients with AML prior to Stem Cell Transplant (ERASE)
Tusamitamab Ravtansine (Tusa) Vs Investigator Choice in CEACAM5+ NSCLC After the Failure of Standard of Care Systemic Therapy
Low and Anaplastic Grade Glioma Umbrella Study of Molecular Guided Therapies (LUMOS2)
The CCTG Annual Spring Meeting of Participants will be held Friday, May 3 to Sunday, May 5 at the Chelsea Hotel in Toronto. Here are some updates if you are planning on joining us.
If you are planning meetings and/or attending the Spring Meeting be sure to read your Invitation carefully so you are clear on the funding support associated with your Invitation.
Clinical trials are the most effective means of ensuring we have better cancer treatments. Such an investment would help overcome many hurdles facing clinical trials – from underfunding and suboptimal testing capacity to inefficient and costly regulatory processes.
By Janet Dancey Contributor
From the Toronto Star Opinion Page - Monday, February 19, 2024
Patient-Reported Outcomes in OlympiA: A Phase III, Randomized, Placebo-Controlled Trial of Adjuvant Olaparib in gBRCA1/2 Mutations and High-Risk Human Epidermal Growth Factor Receptor 2–Negative Early Breast Cancer.